Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070511 · ClinicalTrials.gov registry record · Phase 4
Tadalafil in Becker Muscular Dystrophy
A Phase 4 study of Becker Muscular Dystrophy, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT01070511: Completed Phase 4 study of Becker Muscular Dystrophy, sponsored by Cedars-Sinai Medical Center.
NCT01070511 is a Phase 4 study of Becker Muscular Dystrophy that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 48 participants, below the 1,392-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01070511, a Phase 4 study of Becker Muscular Dystrophy, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
Summary for Patients: This study, funded by the Muscular Dystrophy Association, is intended to build on recent findings published in the journal Nature showing beneficial effects of tadalafil (also known as Cialis) in mice with an animal version of Duchenne and Becker muscular dystrophies. Only two doses of tadalafil improved muscle blood flow, allowing the dystrophic mice to perform more exercise with less muscle injury. This new short-term clinical trial will move the testing from animals to human patients with Becker muscular dystrophy and examine the effects of acute tadalafil dosing on muscle blood flow during a bout of exercise. Patients will take two doses of tadalafil prior to exercising. Then doctors will measure whether muscles receive increased blood flow and therefore are better protected during exercise. Scientific Hypothesis: In patients with Becker muscular dystrophy (particularly those with dystrophin gene mutations between exons 41-46), loss of sarcolemmal nitric oxide synthase engenders functional muscle ischemia and thus muscle edema after an acute bout of exercise. The investigators further hypothesize that PDE5A inhibition, which boosts nitric oxide-cGMP signaling, constitutes an effective new countermeasure for these patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tadalafil
Study Locations (2)
California
- Cedars-Sinai Medical Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
What the finished NCT01070511 record still lists
NCT01070511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 1,392-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Becker Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01070511 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01070511 about?
NCT01070511 is a clinical study titled "Tadalafil in Becker Muscular Dystrophy". Summary for Patients: This study, funded by the Muscular Dystrophy Association, is intended to build on recent findings published in the journal Nature showing beneficial effects of tadalafil (also known as Cialis) in mice with an animal version of Duchenne and Becker muscular dystrophies. Only two ...
What is the current status of trial NCT01070511?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2010-01. Estimated completion is 2012-12.
What conditions does trial NCT01070511 study?
This clinical trial studies the following conditions: Becker Muscular Dystrophy.
What interventions are being tested in trial NCT01070511?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT01070511?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01070511 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Becker Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01070511's enrollment target sits among peer trials
48 9th of 12 higher than 4 of 12 other Becker Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Becker Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Duchenne Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
RECRUITING
-
CureDuchenne Link®: A Resource for Research
RECRUITING
-
Defining Endpoints in Becker Muscular Dystrophy
ACTIVE NOT RECRUITING
-
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia